Medtronic Lands Surprise Approval On Symplicity Spyral

The US FDA’s decision to allow Medtronic to market the Symplicity Spyral renal denervation (RDN) device sets up a rivalry in the RDN market, as the medtech giant’s offering will come up against ReCor’s Paradise system.

Illustration of Symplicity Spyral • Source: Medtronic PLC

Medtronic announced on 17 November that the US Food and Drug Administration has approved the Symplicity Spyral renal denervation (RDN) system for the treatment of hypertension, making it the second RDN device to reach the market. The company plans to launch the product as soon as possible.

Just earlier this month, the FDA approved the first RDN product, ReCor’s Paradise system. (Also see "FDA Approves ReCor’s...

More from Approvals

More from Policy & Regulation